Skip to content
HowShorted

INTERCEPT PHARMACEUTICALS, INC. short interest in 2020

In 2020, INTERCEPT PHARMACEUTICALS, INC.'s disclosed short interest ran from 14.93% of shares outstanding on 15 Jan 2020 to 22.20% on 31 Dec 2020, a change of +7.27 percentage points. The year's high was 22.20% on 31 Dec 2020 and its low 13.48% on 31 Mar 2020, averaging 16.77% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.60 days on 14 Feb 2020. Full history: INTERCEPT PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023

Aggregate net short position time series for INTERCEPT PHARMACEUTICALS, INC. in 2020

2020 in figures

Start of year
14.93% (15 Jan 2020)
End of year
22.20% (31 Dec 2020)
Change
+7.27 pp
High
22.20% (31 Dec 2020)
Low
13.48% (31 Mar 2020)
Average
16.77%
Highest days to cover
13.60 (14 Feb 2020)
SEC filings marked
8

Every report in 2020

INTERCEPT PHARMACEUTICALS, INC. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202014.93%8.44
31 Jan 202015.30%8.22
14 Feb 202014.56%13.60
28 Feb 202014.95%9.3210-K filed, results (8-K)
13 Mar 202014.35%8.25
31 Mar 202013.48%6.57
15 Apr 202013.70%10.43
30 Apr 202015.11%9.26
15 May 202016.63%8.3510-Q filed, results (8-K)
29 May 202017.57%6.16
15 Jun 202017.60%10.77
30 Jun 202019.46%4.43
15 Jul 202017.85%5.76
31 Jul 202017.94%7.91
14 Aug 202016.70%6.4710-Q filed, results (8-K)
31 Aug 202015.67%9.26
15 Sep 202016.74%7.98
30 Sep 202019.45%11.62
15 Oct 202018.15%7.31
30 Oct 202016.88%7.26
13 Nov 202015.89%4.8810-Q filed, results (8-K)
30 Nov 202017.64%10.91
15 Dec 202019.76%8.65
31 Dec 202022.20%6.60

See also: INTERCEPT PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.